OasisLMS

Dr. Harriette Van Spall, cardiologist and clinical trialist at McMaster University, discusses how to implement heart failure guideline-directed medical therapy in patients at risk for or living with atrial fibrillation. She explains how heart failure and AFib share common risk factors under the umbrella of cardiovascular-kidney-metabolic syndrome, with adiposity as a key driver. She synthesizes evidence from pivotal HFpEF trials, including SGLT2 inhibitors, MRAs, GLP-1 receptor agonists, ARBs, and ARNIs, and shows how these therapies benefit patients with or without AFib. She closes with a look at how to apply therapies across heart failure stages and highlights ongoing trials testing new drugs and pacing strategies in HFpEF.

Made possible with support from Medtronic

• Describe the shared risk factors and mechanisms linking heart failure and atrial fibrillation, including the role of adiposity.
• Recognize the challenges of diagnosing HFpEF in patients with atrial fibrillation and the tools available to confirm it.
• Summarize the evidence for SGLT2 inhibitors, MRAs, GLP-1 receptor agonists, ARBs, and ARNIs in HFpEF, including their effects in patients with AFib.
• Apply guideline-directed medical therapy across heart failure stages, including in patients with chronic kidney disease or obesity.
• Identify emerging trials evaluating new drugs and pacing strategies in HFpEF.

Presenter

Harriette Van Spall, MD, MPH, FRCPC
McMaster University | Cardiologist and Clinical Trialist